Home
Join A Case
Contact
More
Class Action Cases
NGM Biopharmaceuticals, Inc.
The investigation focuses on determining if the NGM Bio board breached its fiduciary duties to shareholders. The Company announced on February 26, 2024, that “it has entered into a definitive Agreement and Plan of Merger (the “Merger Agreement”) under which Atlas Neon Parent, Inc. (“Purchaser”) and Atlas Neon Merger Sub, Inc. (“Merger Sub”) will acquire NGM Bio through a cash tender offer to be commenced by Merger Sub for all outstanding shares of NGM Bio not held by affiliates of The Column Group, LP and certain other stockholders, as described below, at a price per share of $1.55 in cash.”
Press Release
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the Firm
Los Angeles, February 27, 2024 — The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in NGM Biopharmaceuticals, Inc. (“NGM Bio” or “the Company”) (NASDAQ: NGM) for potential breaches of fiduciary duty on the part of its directors and management.
The investigation focuses on determining if the NGM Bio board breached its fiduciary duties to shareholders. The Company announced on February 26, 2024, that “it has entered into a definitive Agreement and Plan of Merger (the “Merger Agreement”) under which Atlas Neon Parent, Inc. (“Purchaser”) and Atlas Neon Merger Sub, Inc. (“Merger Sub”) will acquire NGM Bio through a cash tender offer to be commenced by Merger Sub for all outstanding shares of NGM Bio not held by affiliates of The Column Group, LP and certain other stockholders, as described below, at a price per share of $1.55 in cash.”
If you are a shareholder, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at bschall@schallfirm.com.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.
310-301-3335
info@schallfirm.com
www.schallfirm.com